Infinity Pharmaceuticals (INFI) Earns News Sentiment Score of 0.41
News coverage about Infinity Pharmaceuticals (NASDAQ:INFI) has been trending positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 0.41 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.9317323318108 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Monthly Uptick Roundup – Infinity Pharmaceuticals, Inc. (INFI) moved 0.98% – The Stocks News (press release) (thestocksnews.com)
- Infinity Pharmaceuticals (INFI) to Release Quarterly Earnings on Monday (americanbankingnews.com)
- -$0.25 EPS Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter (americanbankingnews.com)
- An Eye on Data – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) – The Investor Guide (wallstreetnews24.com)
- Infinity Pharmaceuticals, Inc. (INFI) sticks almost 2.17% in last 5 trades – Nasdaq Fortune (press release) (nasdaqfortune.com)
Infinity Pharmaceuticals (NASDAQ INFI) traded up $0.14 during trading hours on Monday, hitting $2.21. The stock had a trading volume of 322,960 shares, compared to its average volume of 524,767. The firm has a market cap of $112.07, a PE ratio of -1.94 and a beta of 2.74. Infinity Pharmaceuticals has a twelve month low of $0.93 and a twelve month high of $3.75.
In other Infinity Pharmaceuticals news, President Lawrence E. Bloch acquired 500,000 shares of the stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $1.81 per share, with a total value of $905,000.00. Following the transaction, the president now owns 580,944 shares in the company, valued at approximately $1,051,508.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.81% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Infinity Pharmaceuticals (INFI) Earns News Sentiment Score of 0.41” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/05/infinity-pharmaceuticals-infi-earns-news-sentiment-score-of-0-41.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.